Drug cuts risk of breast cancer recurrence for some early-stage patients, trial shows

(CNN) — A drug used in people in the early stage of the most common kind of breast cancer – HR+/HER2- breast cancer – significantly reduced the risk of the

Related Keywords

United States ,Ohio ,Chicago ,Illinois ,American ,Sara Tolaney ,Alberto Montero ,Shreeram Aradhye ,Dennisj Slamon ,Anupama Goel ,Translational Research In Oncology ,Cnn ,Drug Administration ,Jonsson Comprehensive Cancer Center ,Warner Bros ,Case Western Reserve University School Of Medicine ,Dana Farber Cancer Institute ,Discovery Company ,American Society Of Clinical Oncology ,Novartis ,Mount Sinai Tisch Cancer Center ,Cable News Network Inc ,Uh Seidman Cancer Center ,American Society ,Clinical Oncology ,Comprehensive Cancer Center ,Cancer Center ,Case Western Reserve University School ,News Network ,